



Liquid Biopsy in Gastrointestinal Cancer Disease—from Bench to Beside

Guest Editors:

Dr. Georg F. Weber

Department of Surgery,
University Hospital Erlangen,
Friedrich-Alexander University
Erlangen-Nuremberg, Erlangen,
Germany

Dr. Christoph Kahlert

Department of Surgery, Carl
Gustav Carus University Hospital
Dresden, Technische Universität
Dresden, Dresden, Germany

Deadline for manuscript
submissions:

closed (10 October 2022)

Message from the Guest Editors

Liquid biopsies are in the focus of current cancer research. Liquid biopsies are cancer byproducts (mainly circulating tumor cells (CTC), circulating tumor DNA (ctDNA), tumor exosomes, and tumor-educated blood platelets (TEPs)), easily accessible in blood and other body fluids, and may be foreseen as an alternative to tissue-based diagnostics, as well as gastroenterologic and radiologic screening methods. The use of liquid biopsies may lead to early detection of primary and recurrent cancer disease, to a better control of multidisciplinary therapy regimens and the early detection of therapeutic resistance.

In this Special Issue, we will offer an overview of the various types of liquid biopsies currently investigated in gastrointestinal cancer disease, focus on their possible use as novel diagnostic biomarkers, and highlight their importance as one of the main future research pillars in gastrointestinal cancer disease.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)